Celyad Oncology SA (CYAD)
US1512052002 - ADR
| 2022 (2022-12-31) | 2021 (2021-12-31) | 2020 (2020-12-31) | 2019 (2019-12-31) | 2018 (2018-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||
| Current Assets | ||||||||
| Cash | 12.45M | 30.02M | 17.23M | 39.34M | 40.54M | |||
| Cash Equivalents | N/A | N/A | N/A | 39.34M | 40.54M | |||
| Marketable Securities | N/A | N/A | N/A | 0.00 | 9.20M | |||
| Receivables | 1.47M | 2.59M | 1.13M | 2.85M | 1.36M | |||
| Other Current Assets | 912.00K | 1.69M | 1.34M | 647.00K | 594.00K | |||
| Total Current Assets | 14.82M | 34.29M | 19.70M | 42.84M | 51.69M | |||
| Non-Current Assets | ||||||||
| PPE Net | 309.00K | 3.25M | 4.12M | 5.06M | 3.01M | |||
| Investments And Advances | N/A | N/A | N/A | N/A | N/A | |||
| Goodwill | 0.00 | 883.00K | 883.00K | 883.00K | 883.00K | |||
| Intangibles | 864.00K | 35.28M | 35.29M | 35.32M | 35.28M | |||
| Other Non-Current Assets | 264.00K | 262.00K | 293.00K | 257.00K | 214.00K | |||
| Total Non-Current Assets | 4.89M | 45.65M | 46.38M | 47.00M | 42.61M | |||
| TOTAL ASSETS | 19.72M | 79.94M | 66.08M | 89.84M | 94.30M | |||
| LIABILITIES | ||||||||
| Current Liabilities | ||||||||
| Short Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||
| Current Portion Of LT Debt. | 137.00K | 902.00K | 1.11M | 1.36M | 765.00K | |||
| Accrued Expenses | 1.39M | 2.13M | 1.97M | 2.23M | 1.67M | |||
| Accounts Payable | 4.75M | 6.61M | 4.74M | 6.97M | 5.92M | |||
| Other Current Liabilities | 4.15M | 4.18M | 4.01M | 1.36M | 1.30M | |||
| Total Current Liabilities | 10.43M | 13.83M | 11.83M | 11.92M | 9.65M | |||
| Non-Current Liabilities | ||||||||
| Long Term Debt | 118.00K | 1.73M | 2.52M | 3.00M | 881.00K | |||
| Other Non-Current Liabilities | 4.86M | 20.75M | 20.73M | 29.29M | 28.18M | |||
| Total Non-Current Liabilities | 4.97M | 22.48M | 23.26M | 32.30M | 29.06M | |||
| TOTAL LIABILITIES | 15.40M | 36.30M | 35.09M | 44.22M | 38.71M | |||
| SHAREHOLDERS' EQUITY | ||||||||
| Retained Earnings | -115.39M | -74.44M | -91.83M | -74.42M | -217.78M | |||
| Additional Paid In Capital | 6.32M | 6.32M | 43.35M | 43.35M | 206.15M | |||
| Common Shares | 78.58M | 78.58M | 48.51M | 48.51M | 41.55M | |||
| Other Shareholders' Equity | 34.80M | 33.17M | 30.96M | 28.18M | 25.66M | |||
| Shares Outstanding | 22.59M | 22.59M | 13.94M | 13.94M | 11.94M | |||
| Tangible Book Value per Share | 0.15 | 0.33 | -0.37 | 0.68 | 1.63 | |||
| Total Shareholders' Equity | 4.32M | 43.64M | 30.99M | 45.62M | 55.59M | |||
| TOTAL LIABILITIES AND EQUITY | 19.72M | 79.94M | 66.08M | 89.84M | 94.30M | |||
| Statistics | ||||||||
| Debt/Equity | 0.03 | 0.04 | 0.08 | 0.07 | 0.02 | |||
| Current Ratio | 1.42 | 2.48 | 1.67 | 3.59 | 5.36 | |||
| Return On Assets (ROA) | -207.62% | -33.16% | -26.03% | -31.87% | -39.69% | |||
| Return On Equity (ROE) | -948.23% | -60.75% | -55.51% | -62.76% | -67.33% | |||
All data in EUR